Kornimate/medical-research-clean huggingface dataset:
clinical outcome of endotracheal intubation in non-trauma patients

Conditions: Adverse Effects of Endotracheal Intubation

Summary: the study will involve all adult patients visiting the alexandria university main hospitals' emergency department for reasons other than trauma that will require assisted ventilation via endotracheal intubation. those pre-intubated or intubated post cpr will not be included. the main aim is to evaluate the clinical outcome (complications) of emergency endotracheal intubation and to correlate the incidence and nature of complications associated with tracheal intubations to demographic data and patient characteristics.


Eligibility criteria:
inclusion criteria: * adult patients of both sex with a life threatening impairment of the cardiovascular, respiratory or neurological system requiring emergency endotracheal intubation in the emergency department of alexandria main university hospital. exclusion criteria: * • patients who are less than 18 years of age. * patients intubated out of the hospital. * trauma patients. * patients intubated for cardiac arrest. * failed intubation in the field

Keywords: endotracheal intubation clinical outcome
effect of fresh gas flow on emergence time

Conditions: Bladder Cancer

Summary: the purpose of this study is to evaluate the effect of fresh gas flow on emergence time in patients undergoing transurethral resection of bladder tumor.

the purpose of this study is to evaluate the effect of fresh gas flow (5 l/min vs. 10 l/min) on emergence time in patients undergoing transurethral resection of bladder tumor.

Eligibility criteria:
inclusion criteria: * patients who are scheduled transurethral resection of bladder tumor under general anesthesia * patients aged between 20 and 79 years old * american society of anesthesiologists physical status ≤2 * patients who are voluntarily agreed to this clinical study exclusion criteria: * a long operation (2 hours or longer) * hearing disturbance * cognitive disorder * psychiatric substance abuse * patient's denial
safety and efficacy study of lithium in bipolar disorder

Conditions: Bipolar Disorder; Mania

Summary: the purpose of this study is to determine whether lithium is safe and effective in the treatment of bipolar i disorder subjects with symptoms of acute mania.


Eligibility criteria:
inclusion criteria: * diagnosis of bipolar 1 disorder; * hospitalized or in the process of being hospitalized for a manic or mixed episode exclusion criteria: * history of rapid cycling; * history of hypersensitivity or adverse reaction to lithium

Keywords: bipolar i disorder bipolar disorder lithium
pain scores and complications do not differ at three recovery position after liver biopsy

Conditions: Pain, Acute; Liver Diseases

Summary: liver biopsy is still used as the gold standard in the diagnosis of many liver diseases. during the observation after liver biopsy, patients are hospitalized on their right side, which is the biopsy side, with the thought that adverse events (complications) such as bleeding or bile leakage will be less. patients who do not develop complications after 4-6 hours of observation are discharged home. some of the patients state that the right side-lying position for 4-6 hours is uncomfortable than the biopsy itself, and they prefer to lie on their back. in our study, researchers aim to investigate the rate of complications after biopsy, what recovery position found more acceptable by the patients.

liver biopsy is still used as the gold standard in the diagnosis of many liver diseases. the health practice notification (sut) makes the diagnosis with liver biopsy mandatory for the treatment of chronic viral hepatitis (chronic hepatitis b inf. and chronic hepatitis c inf.). in daily gastroenterology practice, clinicians frequently perform a liver biopsy for the diagnosis of non-alcoholic fatty liver (nash), and to a lesser extent, for the diagnosis of wilson disease and hemochromatosis. during the observation after liver biopsy, patients are hospitalized on their right side, which is the biopsy side, with the argument that there will be less bleeding or bile leakage complications. patients who do not develop complications after 4-6 hours of observation are discharged to their homes. (1) in this study, researchers aimed to investigate the post-biopsy position of patients who were referred to the clinic for liver biopsy, the rate of complications after biopsy, and to what extent the patients found the procedure acceptable according to their post-biopsy position.

Eligibility criteria:
inclusion criteria: 1. cronic hepatitis b i̇nfection 2. chronic hepatitis c i̇nfection 3. nash 4. dili 5. acute or chronic liver damage caused unknown aetiology exclusion criteria: 1.refuse to give written informed consent
efficacy and safety of convalescent plasma in treating covid-19 hospitalized patients

Conditions: COVID-19

Summary: this is a phase ii study. this research study is being conducted to use convalescent donor plasma in seriously ill patients who have covid-19.

this is an open label phase 2 trial assessing the efficacy and safety of anti-sars-cov-2 convalescent plasma in hospitalized patients with acute severe respiratory symptoms from covid-19. symptomatic patients with clinical or radiological interstitial covid-19 pneumonia and within 21 days of onset of symptoms will be enrolled in 2 cohorts - an icu cohort and a hospitalized non-icu cohort.

Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years or older 2. hospitalized as an in-patient with positive covid-19 test by pcr 3. presence of respiratory symptoms with any of severe features as below: * respiratory rate ≥ 24/min * oxygen support \>3l/min by nasal cannula * new onset or worsening of respiratory symptoms with radiologic confirmation of bilateral ground glass opacities that cannot be attributed to another cause 4. patient / hcpoa must agree to storage of blood specimens for future testing. 5. patient / hcpoa is willing and able to provide electronic informed consent and comply with all protocol requirements. if patient is unable to consent due to incapacity, health care poa should be defined and able to consent for the patient. 6. patients are allowed to receive all standard of care. co enrollment in other clinical trials is permitted. exclusion criteria: 1. fcbp with positive pregnancy test (mandatory) 2. breastfeeding females 3. receipt of pooled immunoglobulin (e.g. ivig or other hyperimmune globulin products) in past 14 days. this does not apply to monoclonal antibodies . 4. mechanical ventilation for \> 14 days 5. days from symptom onset \>21 days 6. expected survival \< 72 hours 7. contraindication to transfusion or history of prior reactions to transfusion blood products including any proven history of trali 8. patients who were previously admitted to icu cannot be enrolled in the non-icu cohort. these patients could need icu level care subsequently and at that time point could be considered for icu cohort .

Keywords: covid-19
safety and efficacy study of lum001 in the treatment of cholestatic liver disease in patients with alagille syndrome

Conditions: Alagille Syndrome

Summary: the study is a randomized, double-blind, placebo-controlled study to evaluate the safety and tolerability of lum001. efficacy will be assessed by evaluating the effect of lum001 versus placebo on the biochemical markers and pruritus associated with alagille syndrome.


Eligibility criteria:
inclusion criteria: 1. diagnosis of alagille syndrome 2. evidence of cholestasis 3. moderate to severe pruritus 4. ability to understand and willingness to sign informed consent/assent prior to initiation of any study procedures exclusion criteria: 1. surgical disruption of the enterohepatic circulation 2. liver transplant 3. history or presence of other concomitant liver disease 4. females who are pregnant or lactating 5. known hiv infection
mindfulness-based stress reduction techniques and yoga for treatment of urinary urge incontinence (mbsr-yoga)

Conditions: Urinary Incontinence; Urinary Incontinence, Urge

Summary: many women experience the accidental loss of urine called urge incontinence or overactive bladder (oab) incontinence. women describe this as a sudden, strong desire to pass urine which results in leakage before reaching the toilet. the current usual treatments for urge incontinence include behavioral treatment, physical therapy, and medicines. although these treatments have been found to be effective in research studies, they are less effective over time in general practice. because medicines have side effects, many women stop them. the purpose of this study is to explore different treatments that may provide another option for women with urge incontinence that might be effective. this is an initial study to see if these treatments are at least as effective as the usual treatments. hypothesis: does mind based stress reduction(mbsr)(meditation practices)reduce urinary urge incontinence episodes?


Eligibility criteria:
inclusion criteria: 1. females at least 18 years of age 2. five or more urge urinary incontinence episodes on a three-day voiding diary. urge incontinence episodes will be determined based on voiding diary and subject indication of coincident urge symptoms, allowing self-characterization of incontinence type. 3. urge predominant (urge \>50% of total incontinent episodes) urinary incontinence based on self-reported characterization of incontinent episodes on diary. 4. request for treatment for urge urinary incontinence. 5. subject is able to complete all study related items and interviews. exclusion criteria: 1. any current or recent (past 4 weeks) anticholinergic medication use. patient may discontinue medication and after 4 weeks may be eligible for study. 2. past non-pharmacologic treatment for urge incontinence such as supervised behavioral therapy, supervised or unsupervised physical therapy, supervised biofeedback, and transvaginal electrical stimulation. 3. current symptomatic urinary tract infection that has not resolved prior start of mbsr group. 4. symptoms of pelvic organ prolapse screened by pfdi (pelvic floor disorder inventory question #3) "do you have a bulge or something falling out that you can see or feel in the vaginal area?" 5. previous or currently implanted neuromodulation (sacral or tibial). 6. surgically altered detrusor muscle, such as augmentation cystoplasty. 7. women with known neurologic disease believed to potentially affect urinary function (multiple sclerosis, spinal cord injuries, myasthenia gravis, charcot-marie-tooth disease). 8. in the opinion of the investigator, inability to understand diary instructions and complete 3-day voiding diary. 9. subject has been previously diagnosed with interstitial cystitis or chronic pelvic pain syndrome. 10. currently pregnant or within 6 months postpartum (pregnancy is not excluded for safety reasons but for quality of data)

Keywords: mindfulness mindfulness-based stress reduction meditation yoga
sequential endoscopic lung volume reduction

Conditions: Emphysema; COPD

Summary: patients with heterogenous emphysema benefits from endoscopic lung volume reduction. until now the technique is limited to one lobe. in case of collateral ventilation patients show no improvement. between upper and middle lobe exists the highest collateral flow. the trial examine the hypothesis, that sequential elvr help especially those patients, which have no benefit after lobar exclusion.

patients with heterogenous emphysema undergo elvr, target lobe is the upper lobe right. after 6 weeks the middle lobe will be block too. follow-up period 6 months primary end points: fev 1, 6-minute walk test secondary endpoints. safety, symptom scores number of patients planned 30

Eligibility criteria:
inclusion criteria: * heterogenous emphysema * fev1 \< 45% * rv \> 150% * tlc \> 100% * tlco \< 40% exclusion criteria: * homogeneous emphysema * pregnancy * pco2 \> 50 mmhg

Keywords: endoscopic lung volume reduction, heterogeneous emphysema, interventional bronchoscopy
efficacy of ultraviolet germicidal irradiation (uvgi) devices to decrease the incidence of respiratory infections in nursing homes : a cluster randomized crossover trial

Conditions: Acute Respiratory Infections

Summary: otect is a trial aimed at evaluating the effectiveness of upper room ultraviolet devices in reducing the frequency and severity of respiratory infections in elderly nursing homes. the study takes place in 12 nursing homes in the center of france. it started in october 2024, and its final results will be availble by mid-2026.


Eligibility criteria:
center inclusion criteria: elderly nursing homes (enh): * having a system for monitoring cases of upper and lower respiratory infections among their residents. * agreeing to take part in the study * undertaking to comply with the protocol * accepting the installation of uvgi devices * undertaking to provide all residents or their legal guardians/curators with an individual information leaflet. center non-inclusion criteria: enh: * not wishing to be equipped with uvgi devices in all rooms considered necessary to be equipped by the investigators * having planned a major change to the structure (extension, renovation, closure, requalification, etc.) during the course of the study, which could affect the study population and/or uvgi air treatment devices. individual eligibility criteria individual inclusion criteria: all residents present in one of the participating enh at the start of each of the two study periods, or arriving in one of the participating enh during one of the two periods, will be eligible individual non-inclusion criteria : residents of the enh included in the study who have expressed (personally or through a relative or legal representative) the wish that their personal data not be used for the study will not be included in the study.

Keywords: ultraviolet germicidal irradiation (uvgi); respiratory infections; nursing homes; elderly; cluster randomized crossover trial
conventional vs enhanced recovery after surgery protocols in emergency git surgery

Conditions: Patient Presented With Acute Abdomen; Patient Undergoing Urgent GIT Surgery

Summary: although the eras program is widely used in elective procedures in many surgical subspecialties, the place of this program in emergency surgery remains uncertain probably because of the significant challenges in applying all eras pathways in the emergency setting. nevertheless, the eras program is often modified in elective procedures on an individual and/ or institutional basis and thus may also have a role in the emergency setting albeit in a modified form.

the cases will be randomized simply into two groups, group (a) for conventional care and group (b) for eras. random assignment of intervention will be done after subjects have been assessed for eligibility and recruited. the sealed envelope method will be used for randomization. both groups will have pre-operative ryle inserted, urinary catheter applied, tracheal intubation and with general anesthesia, exploration laparotomy group (a) fatsing for at least 6 hours pre-operative, no restriction of iv fluids and traditional analgesia including opiates. post-operative ambulation-as per patients' own request, removal of urinary catheter when patient ambulates, patient will keep fasting for 3 days postoperative, oral fluids for 3 days, semi-solid for another 3 days and then can take full diet, removal of nasogastric tube just before starting oral fluids, drain removal just before discharge. group (b) preoperative information, education and counselling, if possible, clear fluids are allowed up to 2 h and solids up to 6 h prior to induction of anaesthesia, short acting anesthetic agents,avoid opioid agents, post operative nausea and vomiting prophylaxis, patient will wear well-fitting compression stockings and receive pharmacological prophylaxis with lmwh. encourage to mobilize out of bed after effect of general anesthesia has weaned off, chewing gum, oral magnesium and alvimopan can be started early postoperatively, initiation of feeding-oral sips on day 1, step up day 2 onward, removal of nasogastric tube-immediately after surgery after aspirating the gastric content through nasogastric tube, removal of urinary catheter-after weaning from the effect of general anesthesia and drain removal -anytime within 24 hours;drain will not be removed if fluid is bilious or pus.

Eligibility criteria:
inclusion criteria: * pateint presented with acute abdomen necessitating urgent git surgery exclusion criteria: * known chronic kidney disease/ chronic liver disease patients patients with history of chronic steroid abuse. patient requiring positive pressure ventilator support post operatively for more than 12 hours. patient presented with acute appendicitis or acute cholecystitis. patient refusing for consent
exercise-based telerehabilitation in the cardiac rehabilitation program

Conditions: Coronary Heart Disease

Summary: the intervention will involve a system that comprises a wrist-worn activity tracker and a smartphone app that acts as a medium to link to the healthcare website

feasibility study objective: - to investigate the feasibility and preliminary of exercise-based telerehabilitation before undertaking full-scale rct. randomized control trial objective: - 1. primary objective: to determine the exercise capacity among patients with chd, 2. secondary objectives: to assess patient exercise adherence and determine the changes in other clinical health outcomes. study population: patients with coronary heart disease description of sites/facilities enrolling participants: patient engagement with the cardiac rehabilitation phase 2 (crp2) at the university malaya medical centre (ummc). description of study intervention: this study is a mixed-methods study consisting of a quantitative study (feasibility, preliminary evaluation, and full randomized control trial) and a qualitative study (interviewing). the present study will be conducting a single-blinded, three-arm, parallel over a 12-weeks study period during crp2. measurement will be collected during pre-and post-test.

Eligibility criteria:
inclusion criteria: * adults with 18 years old and above with indexed diagnosis of coronary heart disease (chd) and are referred for cardiac rehabilitation program; * low- and moderate-risk patient category (controlled bp, sinus rhythm at 60-90 bpm, pain score\< 3/10) and received a statement of medical clearance by a cr physician to undertake exercise with minimal supervision; * the patient is willing to wear trackers during waking hours, own a personal smartphone and have access to internet/wi-fi; and * participant must be able to able to read, speak and understand english and malay. exclusion criteria: * heart failure nyha stage 3-4, pulse undetected by trackers; * the participant who cannot detect their pulse through wrist-worn tracker; * do not own a smartphone with the mobile internet/wi-fi ; and * contraindicated for an exercise stress test and concomitant morbidity that limit physical activity and exercise.
routine surgical procedures during covid-19 pandemic: a french nationwide cohort study

Conditions: Surgery; Cataract; Hip Arthroplasty; Knee Arthroplasty; Coronary Stent; Pacemaker; COVID-19 Pandemic

Summary: determine the consequences of covid-19 pandemic on routine targeted surgeries. five surgical procedures were considered : cataract surgery, hip and knee arthoplasties, coronary revascularisation by angioplasty and definitive cardiac stimulation. the objective of the study is to quantify changes of these procedures in 2020 and in 2021 (up to june) compared to 2019 taking into account their annual evolution and according to the type of operation (primary or reoperation/revision) and emergency status, if applicable.


Eligibility criteria:
inclusion criteria: * hospitalizations with at least one act of cataract surgey hip arthroplasty knee arthroplasty coronary angioplasty definitive cardiac stimulation (pacemaker) * between january 1, 2019, and june 30, 2021 exclusion criteria: -hospitalizations for personal identifier problems in the database
nimotuzumab combined with mfolfirinox/gx as postoperative adjuvant therapy in pancreatic cancer

Conditions: Pancreatic Cancer

Summary: this is a prospective, multicenter, single-arm, open-label study. the main purpose of the study is to evaluate the efficacy and safety of nimotuzumab combined with mfolfirinox/gx for postoperative adjuvant treatment of pancreatic cancer.

this clinical study is designed as a prospective, multicenter, single arm, open-label study to evaluate the clinical efficacy and safety of combination nimotuzumab with mfolfirinox/gx as postoperative adjuvant therapy in pancreatic cancer. the main endpoint is disease-free survival (dfs). additional end points included overall survival (os) and safety.

Eligibility criteria:
inclusion criteria: * 1. age 18 years or older, gender unlimited; * 2. eastern cooperative oncology group (ecog) performance status of 0 or 1; * 3. had undergone complete macroscopic resection for pancreatic cancer (r0 or r1 resection) with histological confirmation and with no evidence of distant metastasis as demonstrated by imaging; * 4. no prior tumor therapy; * 5. adequate organ and bone marrow function, defined as follows: white blood cells (wbc) ≥ 3.0×10\^9/l; absolute neutrophil count (anc)≥1.5×10\^9/l; hemoglobin≥9.0 g/dl; platelets≥75×10\^9/l; serum total bilirubin (tbil)≤1.5×uln; aspartate aminotransferase (ast) and alanine aminotransferase (alt) ≤ 2.5 times the upper limit of normal (uln); serum creatinine≤1×uln or estimated creatinine clearance ≥ 50 ml/min; * 6. left ventricular ejection fraction (lvef) ≥ 50%; * 7. fertile subjects are willing to take contraceptive measures during the study period. * 8. good compliance and signed informed consent voluntarily exclusion criteria: * 1. prior systemic anti-tumor therapy, such as chemotherapy, radiotherapy; * 2. participated in other drug clinical trials within 4 weeks; * 3. history of other malignancies; * 4. immunodeficiency, or other immune-related disorders requiring medical intervention; * 5. postoperative complications such as bleeding; * 6. woman who are pregnant or breastfeeding; * 7. drug abuse, or clinical, psychological or social factors that may have an impact on informed consent or the implementation of the study; * 8.known allergy to prescription or any component of the prescription used in this study, including nimotuzumab, oxaliplatin, irinotecan, fluorouracil, gemcitabine, and capecitabine.

Keywords: nimotuzumab mfolfirinox adjuvant therapy pancreatic cancer gx